# Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers

> **NCT00654966** · PHASE2 · COMPLETED · sponsor: **Monash University** · enrollment: 16 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Urotensine II
- **DRUG:** Soluble epoxide hydrolase

## Key facts

- **NCT ID:** NCT00654966
- **Lead sponsor:** Monash University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2011-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654966, "Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00654966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*